Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrelOA
Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inhibitor,is the most important treatment for CAD patients undergoing percutaneous coronary intervention(PCI)to prevent recurrent ischemic events and cardiac death.Clopidogrel is one of the commonly used P2Y12 inhibitors.However,up to 30%of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity(HOPR),which is associated with the increased ischemic risks[1].The causes of HOPR are multifactorial and complex.
Qian Gu;Qin Wang;Rui Hua;Wenhao Zhang;Jianzhen Teng;Jiazheng Ma;Zhou Dong;Xiaoxuan Gong;Chunjian Li;
Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China
临床医学
coronarypatientsmortality
《The Journal of Biomedical Research》 2024 (001)
P.87-91 / 5
supported by the National Natural Science Foundation of China(Grant No.82170351);the Jiangsu Province''s Key Provincial Talents Program(Grant No.ZDRCA2016013);the Special Fund for Key R&D Plans(Social Development)of Jiangsu Province(Grant No.BE2019754).
评论